Actively Recruiting
Study of PF-08634404 Alone or With Enfortumab Vedotin in Adults With Locally Advanced or Metastatic Urothelial Cancer
Led by Pfizer · Updated on 2026-10-08
132
Participants Needed
184
Research Sites
38 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying a new medicine called PF-08634404 for adults with locally advanced or metastatic urothelial cancer, a type of bladder cancer that has spread to nearby tissues or other parts of the body. The study aims to evaluate the safety, effectiveness, and behavior of PF-08634404 in the body, as well as how it affects cancer-related markers. This trial includes adults aged 18 and older who have this type of cancer. The study has two groups Cohort A includes participants who have already received treatment and will receive PF-08634404 alone. Cohort B includes participants who have not had prior treatment and will receive PF-08634404 combined with another cancer medicine called enfortumab vedotin. Both treatments are given through intravenous infusion. Treatment continues as long as it benefits the participant and side effects are manageable. Participants will undergo a screening period to confirm eligibility before starting treatment. During the study, they will have regular visits for treatment, health assessments, scans to monitor cancer progress, and laboratory tests. Researchers will measure outcomes such as the cancers response to treatment, side effects, survival, and drug levels in the body. If the cancer worsens but treatment remains helpful and tolerable, participants may continue treatment with agreement from their doctor and the sponsor. The study follows participants for up to approximately three years.
CONDITIONS
Brief Title
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here